Доклады Академии наукДоклады Академии наук0869-5652The Russian Academy of Sciences1769410.31857/S0869-56524884443-445Research ArticleThe novel element in the mechanism of endogenous regulation of depressive-like statesGaribovaT. L.tata-sosnovka@mail.ruGudashevaT. A.<p>Corresponding Member of the Russian Academy of Sciences</p>tata-sosnovka@mail.ruSeredeninS. B.<p>Academician of the Russian Academy of Sciences</p>tata-sosnovka@mail.ruZakusov Research Institute of Pharmacology1010201948844434451111201911112019Copyright © 2019, Russian academy of sciences2019<p>It was shown previously that cyclo-prolylglycine, an endogenous neuropeptide, is a positive AMPA receptor modulator and is able to increase the content of BDNF in neurons. In the present work it was shown that cyclo-prolylglycine at a dose of 1 mg/kg with subchronic intraperitoneal administration reduces the time of animal immobility to passive control, from 167.6 to 83.6 s on the 12th day of the experiment using the model of learned helplessness in rats. That indicates the presence of antidepressant-like activity. The results of the study allow us to consider that cyclo-prolylglycine is a link in the physiological regulation of a depressive-like state.</p>brain derived neurotrophic factor (BDNF)cyclo-L-prolyl-glycineantidepressant-like activitylearned helplessnessratsмозговой нейротрофический фактор (BDNF)цикло-L-пролилглицинантидепрессивная активностьвыученная беспомощностькрысы[Gudasheva T.A., Boyko S.S., Akparov V.Kh., Ostrovskaya R.U., Skoldinov A.P., Rozantsev G.G., Voronina T.A., Zherdev V.P., Seredenin S.B. // FEBS Letters. 1996. V. 391. P. 149-152.][Tran L.H. Neuroprotection and Neuroegenisis by Administering Cyclic Prolyl Glycine. US Patent № 7232798 // 19.06.07.][Guan J., Gluckman P., Yang P., Krissansen G., Sun X., Zhou Y., Wen J., Phillips G., Shorten P.R., McMahon C.D., Wake G.C., Chan W.H.K., Thomas M.F., Ren A., Moon S., Liu D.-X. // Sci. Rep. 2014. V. 4. Article number 4388.][Гудашева Т.А., Островская Р.У., Трофимов С.С., Воронина Т.А., Сколдинов А.П., Середенин С.Б. // Бюл. экспер. биол. мед. 1999. Т. 116. № 10. С. 411-413.][Гудашева Т.А., Константинопольский М.А., Островская Р.У., Середенин С.Б. // Бюл. экспер. биол. мед. 2001. Т. 131. № 5. С. 547-550.][Поварнина П.Ю., Колясникова К.Н., Николаев С.В., Антипова Т.А., Гудашева Т.А. // Бюл. экспер. биол. мед. 2015. Т. 160. № 11. С. 600-603.][Autry A.E., Monteggia L.M. // Pharmacol. Rev. 2012. V. 64. P. 238-258][Гудашева Т.А., Колясникова К.Н., Антипова Т.А., Середенин С.Б. // ДАН. 2016. Т. 469. № 4. С. 492-495.][Гудашева Т.А., Григорьев В.В., Колясникова К.Н., Замойский В.Л., Середенин С.Б. // ДАН. 2016. Т. 471. № 1. С. 106-108.][Lapidus K.A.B., Soleimani L., Murrough J.W. // Neuropsychiatr. Dis. Treat. 2013. V. 9. P. 1101-1112.][Yin X., Guven N., Dietis N. // Brain.Res. 2016. V. 1652. P. 30-42.][Porsolt R.D., Bertin A., Jalfre M. // Eur. J. Pharmacol. 1978. V. 51. P. 291-294.][Бойко С.С., Жердев В.П., Гудашева Т.А., Коротков С.А., Островская Р.У. // Хим.-фармацевт. журн. 2001. Т. 34. № 9. С.11-13.][Castren E. // Handb. Exp. Pharmacol. 2014. V. 220. P. 461-479.][Karege F., Vaudan G., Schwald M., Perroud N., La Harpe R. // Mol. Brain Res. 2005. V. 136. № 1/2. P. 29-37.]